ADMA vs. ACAD, AKRO, ALLO, FGEN, ASND, RDY, VTRS, ROIV, BBIO, and MRNA
Should you be buying ADMA Biologics stock or one of its competitors? The main competitors of ADMA Biologics include ACADIA Pharmaceuticals (ACAD), Akero Therapeutics (AKRO), Allogene Therapeutics (ALLO), FibroGen (FGEN), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.
ADMA Biologics vs. Its Competitors
ADMA Biologics (NASDAQ:ADMA) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.
ACADIA Pharmaceuticals has higher revenue and earnings than ADMA Biologics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.
ADMA Biologics currently has a consensus target price of $27.67, suggesting a potential upside of 96.64%. ACADIA Pharmaceuticals has a consensus target price of $29.12, suggesting a potential upside of 34.87%. Given ADMA Biologics' stronger consensus rating and higher possible upside, equities research analysts plainly believe ADMA Biologics is more favorable than ACADIA Pharmaceuticals.
In the previous week, ACADIA Pharmaceuticals had 6 more articles in the media than ADMA Biologics. MarketBeat recorded 7 mentions for ACADIA Pharmaceuticals and 1 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.15 beat ACADIA Pharmaceuticals' score of 0.12 indicating that ADMA Biologics is being referred to more favorably in the media.
ADMA Biologics has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.
75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 3.7% of ADMA Biologics shares are held by company insiders. Comparatively, 26.5% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
ADMA Biologics has a net margin of 44.06% compared to ACADIA Pharmaceuticals' net margin of 21.80%. ADMA Biologics' return on equity of 41.01% beat ACADIA Pharmaceuticals' return on equity.
Summary
ADMA Biologics and ACADIA Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get ADMA Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ADMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADMA Biologics Competitors List
Related Companies and Tools
This page (NASDAQ:ADMA) was last updated on 10/6/2025 by MarketBeat.com Staff
